TiGenix: A Deeply Undervalued Stem Cell Company With Upcoming Catalysts – Seeking Alpha
Nasdaq |
TiGenix: A Deeply Undervalued Stem Cell Company With Upcoming Catalysts
Seeking Alpha TiGenix offers a rare investment opportunity with a phase 3 allogeneic adult stem cell therapy product with proven efficacy on an orphan market estimated in excess of $2 billion annually. TiGenix has a proven track record of successful clinical trials … Alternatives to Stem Cell Transplants Supported by Key Medical Breakthroughs … |
